本文關(guān)鍵詞：固本防哮飲對哮喘緩解期模型小鼠IL-17A、IL-10和CXCL10的影響　出處：《南京中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 固本防哮飲 哮喘緩解期 IL-17A IL-10 CXCL10

【摘要】：目的:哮喘是一種慢性炎癥性呼吸道疾病,嚴(yán)重威脅人類的健康,其發(fā)病率和病死率呈逐年增長的趨向。中藥復(fù)方固本防哮飲是全國著名中醫(yī)兒科專家江育仁教授經(jīng)驗方,臨床運用多年,療效確切,其可增強(qiáng)患兒體質(zhì),預(yù)防哮喘發(fā)作,提高患兒的生存質(zhì)量與哮喘長期緩解率。在生物醫(yī)學(xué)領(lǐng)域,已經(jīng)明確了白細(xì)胞介素-17A(IL-17A)、白細(xì)胞介素-10(IL-10)及CXC趨化因子配體10(CXCL10)與哮喘發(fā)生的密切相關(guān)性,固本防哮飲的治療機(jī)制可能與此有關(guān)。本研究采用哮喘緩解期動物模型,研究中藥復(fù)方固本防哮飲對哮喘緩解期小鼠IL-17A、IL-10及CXCL10表達(dá)的影響,觀察其對哮喘緩解期模型小鼠氣道炎癥的影響及防治哮喘的機(jī)制。方法:采用卵蛋白(OVA)致敏和呼吸道合胞病毒(RSV)滴鼻誘導(dǎo)激發(fā)BALB/c雌性小鼠,建立哮喘緩解期動物模型,隨機(jī)分為正常組,模型組,固本防哮飲低、中、高劑量組,孟魯司特鈉組及地塞米松組。觀察各組小鼠的一般行為活動,用ELISA法檢測肺組織中IL-17A、IL-10及CXCL10蛋白的表達(dá)水平,Real-timePCR法檢測肺組織中IL-17A、IL-10、CXCL10mRNA的表達(dá)水平。最后采用統(tǒng)計學(xué)方法進(jìn)行分析處理。結(jié)果:模型組小鼠肺組織中IL-17A、CXCL10表達(dá)均顯著高于正常組(P0.01),而IL-10表達(dá)顯著低于正常組(P0.01);固本防哮飲低、中、高劑量組,孟魯司特鈉組及地塞米松組小鼠肺組織中IL-17A、CXCL10表達(dá)均低于模型組(P0.05),而IL-10表達(dá)高于模型組(P0.05)。相關(guān)性分析顯示,ELISA檢測法中模型組小鼠IL-10與IL-17A、CXCL10表達(dá)均呈負(fù)相關(guān)(r=-0.006、r=-0.637,P0.05),IL-17A與CXCL10表達(dá)呈正相關(guān)(r=0.896,P0.05)。結(jié)論:1.哮喘緩解期氣道炎癥可能與IL-17A、IL-10及CXCL10水平的改變有關(guān)。2.固本防哮飲對IL-17A、IL-10及CXCL10的表達(dá)有一定的調(diào)節(jié)作用。3.固本防哮飲治療哮喘的作用機(jī)制可能是通過上調(diào)IL-10水平,降低IL-17A、CXCL10水平,減輕氣道炎性反應(yīng),從而達(dá)到防治哮喘的目的。
[Abstract]:Objective: asthma is a chronic inflammatory respiratory disease, which is a serious threat to human health. The incidence and mortality of asthma are increasing year by year. The traditional Chinese medicine prescription "Ben Ben Wei Xiao" is a famous Chinese pediatrics expert, Professor Jiang Yuren. It has been used for many years, and its curative effect is definite. It can enhance the physical fitness of children, prevent asthma attacks, improve the quality of life and long-term remission rate of asthma. In the field of biomedicine, it has been clear that interleukin -17A (IL-17A), interleukin -10 (IL-10) and CXC chemokine ligand 10 (CXCL10) are closely related to asthma. In this study, we adopted the animal model of asthma remission stage to study the effect of Chinese herbal medicine "Ben Ben Xiao Xiao Yin" on the expression of IL-17A, IL-10 and CXCL10 in asthmatic mice, and to observe its effect on airway inflammation in asthmatic remission model mice and the mechanism of preventing and treating asthma. Methods: using ovalbumin (OVA) sensitization and respiratory syncytial virus (RSV) nasal induced BALB/c female mice to establish animal model of asthma, were randomly divided into normal group, model group, gbfxd low, medium and high dose group, montelukast sodium group and dexamethasone pine group. The general behavioral activities of mice were observed. The expression levels of IL-17A, IL-10 and CXCL10 protein in lung tissue were detected by ELISA. The expression levels of IL-17A, IL-10 and CXCL10mRNA in lung tissue were detected by Real-timePCR. Finally, the statistical method is used to analyze and deal with it. Results: IL-17A were significantly higher than the normal group, the expression of CXCL10 in lung tissue of mice in the model group (P0.01), and the expression of IL-10 was significantly lower than that of normal group (P0.01); gbfxd low, medium and high dose group were lower than the model group, the expression of CXCL10 IL-17A Meng Lu Lester sodium and dexamethasone in lung tissue of mice in (P0.05), and the expression of IL-10 is higher than that of the model group (P0.05). Correlation analysis showed that IL-10 expression was negatively correlated with IL-17A and CXCL10 expression in model group mice (r=-0.006, r=-0.637, P0.05), and IL-17A was positively correlated with CXCL10 expression (r=0.896, P0.05) in ELISA detection. Conclusion: 1. airway inflammation in the remission period of asthma may be associated with changes in the levels of IL-17A, IL-10 and CXCL10. 2. the expression of IL-17A, IL-10 and CXCL10 had a certain regulating effect. 3., the effective mechanism of "Gu Ben Xiao Xiao Yin" in treating asthma is probably by increasing the level of IL-10, decreasing the level of IL-17A and CXCL10, and reducing the inflammatory reaction of airway, so as to achieve the purpose of preventing and treating asthma.
【學(xué)位授予單位】：南京中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R285.5;R-332

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 袁雪晶;孫軼秋;王素梅;李燕寧;王孟清;;固本防哮飲聯(lián)合定喘敷貼膏治療兒童哮喘緩解期療效評價[J];世界中醫(yī)藥;2016年09期

2 陳鄭宇;周t，

本文編號：1345200